Dual Pathway Inhibition: A Different Antithrombotic Strategy for Patients With CAD/PAD

Host: Jennifer Caudle, DO <br> Guest: Sandeep Nathan, MD <br> <p>Tune in as Dr Sandeep Nathan discusses treatment guidelines for thrombotic risk reduction in patients with chronic CAD/PAD and shares data on these patients from the REACH Registry. Dr Nathan will also explain a different treatment paradigm, dual pathway inhibition, using XARELTO^® 2.5 mg twice daily plus low-dose aspirin once daily for the reduction in the risk of major cardiovascular events.</p> <p>This promotional educational activity is brought to you by Janssen Pharmaceuticals, Inc., and is not certified for continuing medical education. The consultant is a paid speaker for Janssen Pharmaceuticals, Inc. The speaker is presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.</p>